-- The stock added 2.6% after beating expectations for the second quarter. The company reported adjusted earnings of 52 cents per share, while analysts polled by Refinitiv expected 22 cents. Revenue came in slightly lower, however, with the company reporting $3.68 billion against a forecast of $3.69 billion.
- Shares of the pharmaceutical company surged nearly 30% in premarket trading after Apellis released a safety update about Syfovre, a drug used to treat a degenerative eye disease. Apellis said that no direct cause has been found between a side effect and a particular filter needle used with Syfovre, but that practitioners should use a different filter needle instead.
Italia Ultime Notizie, Italia Notizie
Similar News:Puoi anche leggere notizie simili a questa che abbiamo raccolto da altre fonti di notizie.
Fonte: NBCNewYork - 🏆 270. / 63 Leggi di più »
Fonte: MarketWatch - 🏆 3. / 97 Leggi di più »